PRICENTRIC BRIEF:
- Come July 2021, Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) will be subject to a 4.3% price reduction due to cost-effectiveness assessment (CEA)-induced price adjustments
- The Ministry of Health, Labor, and Welfare (MHLW) formulated a plan to lower prices for products with significantly high prices—categorized as an H3 medicine, Kymriah was deemed eligible for CEA-based price cuts by the Central Social Insurance Medical Council (Chuikyo)
- Yescarta will be given a national health insurance (NHI) price this month after backing from Chuikyo and be subject to a price adjustment, akin to that of Kymriah: Yescarta was categorized as an H5 product, or a product like those in categories H1-H4 and for which reference drugs used in pricing (i.e. Kymriah) are subject to CEAs
THE DETAILS
TOKYO, Japan – Come July 2021, Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) will be subject to a 4.3% price reduction due to cost-effectiveness assessment (CEA)-induced price adjustments, according to Pharma Japan.
The Ministry of Health, Labor, and Welfare (MHLW) formulated a plan to lower prices for products with significantly high prices—categorized as an H3 medicine, Kymriah was deemed eligible for CEA-based price cuts by the Central Social Insurance Medical Council (Chuikyo).
In May 2019, Kymriah was approved at a price of JPY 33,493,407 (public price including VAT, according to data from Pricentric). To price Kymriah, Japan used a cost-based method, as there are no specific pricing policies in place for such medicines; treatments like Kymriah are grouped as “regenerative medicines.”
The CAR-T therapy initially earned a 35% utility premium for its anti-tumor effect and a 10% marketability premium for its orphan drug designation, however, the premium rate for Kymriah was reduced by 80% to just 9% under a rule introduced the year prior for drugs priced by the cost-based method that reduces launch premium rates based on the ratio of disclosed costs.
Earlier this year, Daiichi Sankyo’s CAR-T therapy Yescarta (axicabtagene ciloleucel) secured approval from the MHLW and is being priced by the comparator method of pricing, with Kymriah serving as the comparator treatment.
Yescarta will be given a national health insurance (NHI) price this month after backing from Chuikyo and be subject to a price adjustment, akin to that of Kymriah. Yescarta was categorized as an H5 product, or a product like those in categories H1-H4 and for which reference drugs used in pricing (i.e. Kymriah) are subject to CEAs.
Learn more about Pricentric ONE and our Global Pricing Solutions!
Contact us with your questions and global pricing needs, and an expert will follow up shortly.